Plasma Extracellular Vesicle alpha-Synuclein Level in Patients with Parkinson's Disease

doi:10.3390/biom11050744

CNU IR > College of Sustainable Environment and Recreation > Dept. of Recreation and Health-Care Management > Periodical Articles > Item 310902800/34428

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34428

Title:	Plasma Extracellular Vesicle alpha-Synuclein Level in Patients with Parkinson's Disease
Authors:	Chung, Chen-Chih Chan, Lung Chen, Jia-Hung Hung, Yi-Chieh Hong, Chien-Tai
Contributors:	Taipei Med Univ, Dept Neurol, Shuang Ho Hosp Taipei Med Univ, Sch Med, Dept Neurol, Coll Med Taipei Med Univ, Grad Inst Biomed Informat Chi Mei Med Ctr, Dept Neurosurg, Dept Surg Chia Nan Univ Pharm & Sci, Dept Recreat & Healthcare Management
Keywords:	extracellular vesicles Parkinson's disease akinetic-rigidity alpha-synuclein
Date:	2021
Issue Date:	2023-11-11 11:52:13 (UTC+8)
Publisher:	MDPI
Abstract:	Background: The most established pathognomonic protein of Parkinson's disease (PD), alpha-synuclein, is extensively investigated for disease diagnosis and prognosis; however, investigations into whether the free form of alpha-synuclein in the blood functions as a PD biomarker have not been fruitful. Extracellular vesicles (EVs) secreted from cells and present in blood transport molecules are novel platforms for biomarker identification. In blood EVs, alpha-synuclein originates predominantly from the brain without the interference of the blood-brain barrier. The present study investigated the role of plasma EV-borne alpha-synuclein as a biomarker of PD. Methods: Patients with mild to moderate stages of PD (n = 116) and individuals without PD (n = 46) were recruited to serve as the PD study group and the control group, respectively. Plasma EVs were isolated, and immunomagnetic reduction-based immunoassay was used to assess EV alpha-synuclein levels. Conventional statistical analysis was performed using SPSS 25.0, and p < 0.05 was considered significant. Results: Compared with controls, we observed significantly lower plasma EV alpha-synuclein levels in the patients with PD (PD: 56.0 +/- 3.7 fg/mL vs. control: 74.5 +/- 4.3 fg/mL, p = 0.009), and the significance remained after adjustment for age and sex. Plasma EV alpha-synuclein levels in the patients with PD did not correlate with age, disease duration, Part I and II scores of the Unified Parkinson's Disease Rating Scale (UPDRS), or the Mini-Mental State Examination scores. However, such levels were significantly correlated with UPDRS Part III score, which assesses motor dysfunction. Furthermore, the severity of akinetic-rigidity symptoms, but not tremor, was inversely associated with plasma EV alpha-synuclein level. Conclusion: Plasma EV alpha-synuclein was significantly different between the control and PD group and was associated with akinetic-rigidity symptom severity in patients with PD. This study corroborates the possible diagnostic and subtyping roles of plasma EV alpha-synuclein in patients with PD, and it further provides a basis for this protein's clinical relevance and feasibility as a PD biomarker.
Relation:	BIOMOLECULES, v.11, n.5
Appears in Collections:	[Dept. of Recreation and Health-Care Management] Periodical Articles

Files in This Item:

File	Description	Size	Format
biom11050744.pdf		999Kb	Adobe PDF	83	View/Open
index.html		0Kb	HTML	304	View/Open

Loading...